Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.

Abstract:

:Indolent non-Hodgkin's lymphoma (iNHL) describes a group of B-cell lymphomas with a long median survival and a relapsing-remitting clinical course. Although existing treatments are initially effective, patients often relapse, demonstrating decreasing efficacy with successive treatment courses. Alternative treatments are needed. PI3Kδ plays an essential, non-redundant role in B-cell receptor signaling critical to the pathogenesis of iNHL. It is expressed predominantly in hematopoietic cells, making PI3Kδ an attractive therapeutic target. Idelalisib is an oral PI3Kδ inhibitor approved in 2014 in the USA and the EU as monotherapy in relapsed follicular lymphoma or relapsed small lymphocytic lymphoma previously treated with two or more prior systemic therapies, or as part of combination therapy with rituximab in patients with chronic lymphocytic leukemia, for whom rituximab monotherapy would be considered appropriate due to the presence of comorbidities. Herein, we review the available data for idelalisib, with an emphasis on relapsed/refractory B-cell iNHL.

journal_name

Expert Rev Hematol

authors

Davies A

doi

10.1586/17474086.2015.1071663

subject

Has Abstract

pub_date

2015-10-01 00:00:00

pages

581-93

issue

5

eissn

1747-4086

issn

1747-4094

journal_volume

8

pub_type

杂志文章,评审
  • Lestaurtinib: a multi-targeted FLT3 inhibitor.

    abstract::Internal tandem duplication mutations of FMS-like tyrosine kinase-3 (FLT3) have been associated with poor outcomes in acute myelogenous leukemia. Over the course of the last several years, multiple agents have been developed and studied as potential inhibitors of FLT3 with the hope of providing clinical benefit for th...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2.1.17

    authors: Fathi AT,Levis M

    更新日期:2009-02-01 00:00:00

  • Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.

    abstract:INTRODUCTION:Peripheral T cell lymphomas (PTCL) are a heterogenous group of lymphoproliferative disorders which are generally not curable with conventional chemotherapy and associated with inferior outcomes. Pralatrexate is a novel folate analog, the first FDA approved drug) for the treatment of relapsed/refractory (R/...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1756257

    authors: Jennifer C Z,Sara Mohamed J,Salma A,Francine F

    更新日期:2020-06-01 00:00:00

  • Incorporating placental tissue in cord blood banking for stem cell transplantation.

    abstract:INTRODUCTION:Human term placenta is comprised of various tissues from which different cells can be obtained, including hematopoietic stem cells and mesenchymal stem/stromal cells (MSCs). Areas covered: This review will discuss the possibility to incorporate placental tissue cells in cord blood banking. It will discuss ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1483717

    authors: Teofili L,Silini AR,Bianchi M,Valentini CG,Parolini O

    更新日期:2018-08-01 00:00:00

  • Analysis of Hb levels and degree of anemia in relation to genotype in 615 patients with hemoglobin H disease.

    abstract:OBJECTIVES:We analyzed hemoglobin (Hb) levels and degree of anemia in relation to genotype in patients with hemoglobin H (Hb H) disease, thereby providing a scientific basis for the prevention and treatment of Hb H disease in the Guangxi region of China. METHODS:Hb analysis was conducted in 615 patients using high per...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1803736

    authors: Luo S,Chen X,Chen L,Zhong Q,Wang Q,Xu Z,Huang J,Yan T,Tang N

    更新日期:2020-09-01 00:00:00

  • One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic

    abstract::Key paper evaluation: Craddock C, et al. Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia. J Clin Oncol. 2019; 37: 580-8. Allogeneic hematopoietic stem cell transplant (allo-HSCT) is the only potentially cura...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2019.1635005

    authors: Bewersdorf JP,Stahl M,Zeidan AM

    更新日期:2019-08-01 00:00:00

  • Risk assessment of venous thromboembolism in hematological cancer patients: a review.

    abstract::Introduction: Venous thromboembolism (VTE) is a frequent and serious complication in cancer patients. Nonetheless, patients with hematological cancers receive less attention as compared with their solid tumor counterparts regarding this potentially fatal complication.Areas covered: Risk factors that are associated wit...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1751608

    authors: Chan TS,Hwang YY,Tse E

    更新日期:2020-05-01 00:00:00

  • Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art.

    abstract::Anti-CD20 monoclonal antibodies (mAbs), rituximab, ofatumumab and obinutuzumab, have a significant impact in the treatment of chronic lymphocytic leukemia (CLL), particularly in combination with chemotherapy. Over the last few years, several new mAbs have been developed and investigated in CLL. The most promising newe...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2014.963048

    authors: Robak T

    更新日期:2014-12-01 00:00:00

  • Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.

    abstract::Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukem...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2016.1144469

    authors: Hou HA,Tien HF

    更新日期:2016-05-01 00:00:00

  • An update on biology, diagnosis and treatment of primary plasma cell leukemia.

    abstract:INTRODUCTION:Primary plasma cell leukemia (PPCL) is one of the most aggressive hematological malignancies. The prognosis of PPCL patients remains poor, although some improvements have been made in recent years. Areas covered: In this review recent clinical and biological advances in PPCL are reported. Some recommendati...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1598258

    authors: Musto P,Statuto T,Valvano L,Grieco V,Nozza F,Vona G,Bochicchio GB,La Rocca F,D'Auria F

    更新日期:2019-04-01 00:00:00

  • Position paper on management of iron deficiency in adult cancer patients.

    abstract:INTRODUCTION:Disorders of iron metabolism are commonly seen in onco-hematological clinical practice. Iron-deficiency anemia and cancer-associated anemia are usually treated with supportive therapies. Optimal management of these conditions are discussed in this perspective paper. Areas covered: A position paper discussi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2017.1343140

    authors: Barni S,Gascòn P,Petrelli F,García-Erce JA,Pedrazzoli P,Rosti G,Giordano G,Mafodda A,Múñoz M

    更新日期:2017-08-01 00:00:00

  • Ferumoxytol for the treatment of iron deficiency.

    abstract::Intravenous iron is standard for dialysis-associated anemia and its use is rising dramatically in other settings. Except for the dextrans, full iron replacement requires multiple visits. Nonetheless, safety concerns abound. Ferumoxytol, a recently approved modified dextran with a carbohydrate core that tightly binds t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.31

    authors: Rosner MH,Auerbach M

    更新日期:2011-08-01 00:00:00

  • Bronchial myeloid sarcoma with concurrent Aspergillus fumigatus infection in a patient presenting with hemoptysis.

    abstract::Myeloid sarcoma (MS) is an extramedullary myeloid neoplasm characterized by proliferation of myeloblasts which can occur in any organ or site. Bronchial and pulmonary involvement, however, is uncommon. We describe a case of bronchial MS in an 81-year-old female with a history of high-grade myelodysplastic syndrome; sh...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/17474086.2015.1044747

    authors: Vennepureddy A,Valecha G,Murukutla S,Hussein S,Terjanian T

    更新日期:2015-08-01 00:00:00

  • Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease.

    abstract:INTRODUCTION:Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are considered indolent lymphocytic malignancies, more often requiring active surveillance rather than intervention. Despite the indolent nature of CLL/SLL, treatment is likely indicated in a patients' lifetime. Recent changes in the t...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1270203

    authors: Tees MT,Flinn IW

    更新日期:2017-02-01 00:00:00

  • The importance of inhibitor eradication in clinically complicated hemophilia A patients.

    abstract:INTRODUCTION:Inhibitors against factor VIII (FVIII), which develop in around 20-30% of patients with severe hemophilia A, represent a significant complication of on-demand or prophylactic FVIII therapy. Currently, the main treatment option for inhibitor patients is eradication using immune tolerance induction (ITI) the...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2018.1521718

    authors: Oldenburg J,Young G,Santagostino E,Escuriola Ettingshausen C

    更新日期:2018-11-01 00:00:00

  • Ponatinib in the therapy of chronic myeloid leukemia.

    abstract:INTRODUCTION:Chronic Myeloid Leukemia (CML) is a myeloproliferative disorder that has become the neoplastic poster child for understanding the disease biology of a malignant disease and targeting effective therapy. The targeted therapy of BCR-ABL inhibition by tyrosine kinase inhibitors (TKI) has provided the epitome f...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2016.1232163

    authors: Poch Martell M,Sibai H,Deotare U,Lipton JH

    更新日期:2016-10-01 00:00:00

  • Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.

    abstract::Allogeneic hematopoietic stem cell transplantation is still the only potentially curative treatment for patients with myelodysplastic syndromes. Improvements in donor selection, supportive care and the introduction of reduced-intensity conditioning have led to a decrease in early transplant mortality. However, relapse...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.11.58

    authors: Sockel K,Ehninger G,Hofbauer LC,Platzbecker U

    更新日期:2011-12-01 00:00:00

  • Aggressive Non-Hodgkin lymphomas: risk factors and treatment of central nervous system recurrence.

    abstract::Introduction: Secondary central nervous system lymphoma (SCNSL) is a potentially fatal event in the setting of aggressive Non-Hodgkin Lymphomas. Nowadays, despite of the very poor outcome of SCNSL, several studies are going to identify the high-risk patients' subgroup that could early develop this detrimental event an...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1643232

    authors: Santambrogio E,Nicolosi M,Vassallo F,Castellino A,Novo M,Chiappella A,Vitolo U

    更新日期:2019-09-01 00:00:00

  • CD43 in the malignant flow cytometry laboratory in 2020.

    abstract::Objectives: CD43 can be useful in routine flow cytometry. We conducted a systematic review aiming to describe when CD43 is used by flow cytometry in malignant hematology and to determine its value in these settings. Methods: Systematic review of MEDLINE (search 'CD43' AND 'flow cytometry,' starting in 2010). Results: ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2021.1856653

    authors: Sorigue M

    更新日期:2021-01-01 00:00:00

  • Pathways to pulmonary hypertension in sickle cell disease: the search for prevention and early intervention.

    abstract:INTRODUCTION:Pulmonary hypertension (PH) develops in a significant number of patients with sickle cell disease (SCD), resulting in increased morbidity and mortality. This review focuses on PH pathophysiology, risk stratification, and new recommendations for screening and treatment for patients with SCD. Areas covered: ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2017.1364989

    authors: Shilo NR,Morris CR

    更新日期:2017-10-01 00:00:00

  • Considerations when restarting anticoagulants in patients with atrial fibrillation after bleeding.

    abstract::Introduction: Oral anticoagulants (OACs) are established treatments to reduce thromboembolic risk in patients with atrial fibrillation (AF). Due to their mechanisms of action, they are associated with increased bleeding risk. Evaluation with bleeding risk scores may be useful to identify patients at high risk. However...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2019.1647779

    authors: Kozieł M,Ding WY,Kalarus Z,Lip GYH

    更新日期:2019-10-01 00:00:00

  • Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need.

    abstract::In chronic lymphocytic leukemia (CLL), the most prevalent lymphoid malignancy in western countries, patients have a median age at diagnosis of 72 years. In the last few years, there has been remarkable progress in understanding the biology of CLL, the detection of molecular prognostic factors and the development of mo...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2013.814845

    authors: Molica S,Brugiatelli M,Morabito F,Ferrara F,Iannitto E,Di Renzo N,Capalbo S,Musto P,Di Raimondo F

    更新日期:2013-08-01 00:00:00

  • Eltrombopag for the treatment of immune thrombocytopenia.

    abstract::Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a low platelet count that has persisted for more than 12 months. Patients with severe, symptomatic disease may have significant morbidity and require treatment. Historically, the underlying cause of ITP was believed to be accelerated plat...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1586/ehm.11.25

    authors: Cheng G

    更新日期:2011-06-01 00:00:00

  • Therapeutic approaches to non-Hodgkin's lymphoma in the elderly patient.

    abstract::The incidence of non-Hodgkin's lymphoma (NHL) is increasing among all age groups, with a median age at diagnosis of 67 years. With the increase in the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients is affected by ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.09.7

    authors: Ninan MJ,Morrison VA

    更新日期:2009-04-01 00:00:00

  • Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma.

    abstract:INTRODUCTION:Immune surveillance is the dynamic process whereby the immune system identifies and kills tumor cells based on their aberrant expression of stress-related surface molecules or presentation of tumor neoantigens. It plays a crucial role in controlling the initiation and progression of hematologic cancers suc...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1755958

    authors: Nesic M,El-Galaly TC,Bøgsted M,Pedersen IS,Dybkær K

    更新日期:2020-06-01 00:00:00

  • Iron overload and allogeneic hematopoietic stem-cell transplantation.

    abstract::Iron overload is frequently observed in patients with hematologic diseases before and after allogeneic stem-cell transplantation because they usually receive multiple red blood cell transfusions. Elevated pretransplant serum ferritin levels, which are widely used as indicators of body iron status, are significantly as...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/ehm.10.81

    authors: Kanda J,Kawabata H,Chao NJ

    更新日期:2011-02-01 00:00:00

  • Large granular lymphocytic leukemia. Current diagnostic and therapeutic approaches and novel treatment options.

    abstract:INTRODUCTION:Large granular lymphocytic leukemia (LGLL) is a low grade lymphoproliferative disorder characterized by the clonal proliferation of large granular lymphocytes (LGL) and recognised by the WHO. The diagnosis and management of these patients is challenging due to the limited information from prospective studi...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1284585

    authors: Matutes E

    更新日期:2017-03-01 00:00:00

  • Current options to manage Waldenström's macroglobulinemia.

    abstract:INTRODUCTION:Waldenström's macroglobulinemia (WM) is a rare, incurable B-cell lymphoma, with a median survival of 5-10 years in symptomatic patients. There is no consensus on the standard of care and several agents are currently used in these patients. Areas covered: In this article, we will review the use of standard ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1080/17474086.2017.1339596

    authors: Benevolo G,Nicolosi M,Santambrogio E,Vitolo U

    更新日期:2017-07-01 00:00:00

  • Safety issues and management of toxicities associated with new treatments for multiple myeloma.

    abstract:INTRODUCTION:In the last decade, the availability of new drugs for the treatment of Multiple Myeloma (MM) significantly improved patients' outcomes, but also raised attention towards a new spectrum of adverse events. Recently, four novel agents with different mechanisms of action (carfilzomib, elotuzumab, daratumumab a...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,meta分析,评审

    doi:10.1080/17474086.2017.1284584

    authors: Brioli A,Mügge LO,Hochhaus A,Von Lilienfeld-Toal M

    更新日期:2017-03-01 00:00:00

  • Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?

    abstract::Introduction: Myelodysplastic Syndrome (MDS) represents a group of cancers characterized by abnormal blood cell formation and maturation, leading to various degrees of cytopenias and potential transformation to acute myeloid leukemia. Deletion of the long arm of chromosome 5 (del(5q)) is the most common clonal chromos...

    journal_title:Expert review of hematology

    pub_type: 杂志文章

    doi:10.1080/17474086.2020.1730806

    authors: Gorshein E,Weber UM,Gore S

    更新日期:2020-03-01 00:00:00

  • Ofatumumab for the treatment of chronic lymphocytic leukemia.

    abstract::Ofatumumab is a humanized second-generation monoclonal antibody with the affinity to a transmembrane protein CD20. In in vitro studies, it exhibits higher efficacy towards chronic lymphocytic leukemia (CLL) cells compared to rituximab, and it can be explained by the fact that its epitope on the target CD20 protein is ...

    journal_title:Expert review of hematology

    pub_type: 杂志文章,评审

    doi:10.1586/17474086.2015.1037736

    authors: Grosicki S

    更新日期:2015-06-01 00:00:00